Takahashi Y, Hagino T, Uchiyama A, Saeki H, et al. Effectiveness, biomarker transition, and safety of 48-week tralokinumab treatment for atopic dermatitis: real-world analyses stratified by age groups (15-17, 18-64, and >/= 65 years). Eur J Dermatol 2026;36:156-165.
PMID: 42183692